



EXCLUSIVE INVITATION for
Empire State Hematology & Oncology Society members
Enjoy **75% off registration** with code **ESHOS75**

This activity
is approved
for **AMA PRA**
Category 1
Credit™.


40th Annual CFS®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

NOVEMBER 9 – 11, 2022

New York Marriott Marquis • New York, NY



Now in its 40th year, the **Chemotherapy Foundation Symposium® (CFS®)** brings together thousands of health care professionals for an exciting 3-day conference that promotes the delivery of evidence-based, state-of-the-art cancer care. Internationally renowned faculty will discuss the latest developments in cancer therapeutics, offering you a unique opportunity to learn how innovative approaches fit into existing treatment paradigms for optimal patient care.

 **PER**®
Physicians'
Education
Resource, LLC
gotoper.com



Scan with smartphone or visit the link below
gotoper.com/cfs22

CO-CHAIRS



Ajai Chari, MD
 Icahn School of Medicine
 at Mount Sinai
 New York, NY



Benjamin P. Levy, MD
 Sibley Memorial Hospital
 Washington, DC



Tiffany A. Traina, MD
 Weill Cornell Medicine
 New York, NY

AGENDA

Wednesday, November 9, 2022

| | | |
|---|--|---|
| 7:00 AM | Welcome, Introductions, and Pre-session Survey | Ajai Chari, MD |
| HEMATOLOGY | | |
| Acute Leukemias | | |
| | | Moderator: Pinkal Desai, MD, MPH |
| 7:15 AM | Updates in Newly Diagnosed ALL | Jae H. Park, MD |
| 7:30 AM | How to Treat: ELN Unfavorable Risk AML | Gail J. Roboz, MD |
| 7:45 AM | How to Treat: ELN Low/Intermediate Risk | Alexander E. Perl, MD, MS |
| 8:00 AM | Which Patients With Intermediate and Favorable Risk Should Be Transplanted? A Look at the Referral Process | Sergio A. Giralt, MD, FACP |
| 8:15 AM | Panel Discussion and Question-and-Answer | All Faculty |
| 8:30 AM | Lymphomas | Moderator: Lori Leslie, MD |
| 9:30 AM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 9:45 AM | Break (Exhibit Hall Open) | |
| 10:15 AM | Chronic Lymphocytic Leukemia | Moderator: Lori Leslie, MD |
| 11:15 AM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 11:30 AM | Medical Crossfire®: TBA | Moderator: Ajai Chari, MD |
| 11:50 AM | LUNCH/Non-CE Symposia | |
| 1:05 PM | Welcome, Introductions, and Pre-session Survey | |
| 1:10 PM | COVID, Vaccinations, and Cancer Treatment | TBA |
| Myeloproliferative Neoplasms (MPNs)/Myelodysplastic Syndrome (MDS) | | |
| | | Moderator: Pinkal Desai, MD, MPH |
| 1:30 PM | Targeted Therapies in MDS: Is There a Role? | Hetty Carraway, MD, MBA, FACP |
| 1:45 PM | Characterizing Prediction of MDS Risk Beyond IPSS | Mikael A. Sekeres, MD, MS |
| 2:00 PM | Disease-Modifying Agents in Polycythemia Vera (PV) | Ellen K. Ritchie, MD |
| 2:15 PM | Updates in Myelofibrosis (MF) Management | John Mascarenhas, MD |
| 2:30 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 2:45 PM | Break (Exhibit Hall Open) | |
| Other Issues in Hematologic Malignancies | | |
| | | Moderator: Ajai Chari, MD |
| 3:15 PM | PTCL Topic | TBA |
| 3:30 PM | How to Manage Breakthrough Hemolysis and Thrombocytopenia in Paroxysmal Nocturnal Hemoglobinuria (PNH) | TBA |
| 3:45 PM | TBA | TBA |
| 4:00 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| Multiple Myeloma (MM) | | |
| | | Moderator: Marc Braunstein, MD, PhD, FACP |
| 4:15 PM | Frontline Therapy for Transplant-Eligible and Transplant-Ineligible Patients | Marc Braunstein, MD, PhD |
| 4:30 PM | Integrating Minimal Residual Disease (MRD) Into Maintenance MM Therapy | Noa Biran, MD |
| 4:45 PM | New Therapeutic Agents for Relapsed/Refractory MM: CAR T and Bispecific Antibodies | Faith Davies, MBBCh, MRCP, MD, FRCPath |
| 5:00 PM | Treating Waldenstrom Macroglobulinemia | Steven Treon, MD, PhD |
| 5:15 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 5:30 PM | Closing Remarks/Adjourn | |
| 5:40 PM | Non-CE Symposia | |

Thursday, November 10, 2022

| | | |
|-----------------------------|---|---|
| 7:00 AM | Welcome, Introductions, and Pre-session Survey | Tiffany A. Traina, MD |
| 7:15 AM | Gynecologic Oncology | Moderator: Eirwen M. Miller, MD |
| 8:00 AM | Medical Crossfire®: TBA | Moderator: TBA |
| 8:20 AM | Panel Discussion and Question-and-Answer | All Faculty |
| Dermatologic Cancers | | Moderator: Richard D. Carvajal, MD |
| 8:35 AM | Neoadjuvant and Adjuvant Therapeutic Approaches for Melanoma | Sapna Patel, BA, MD |
| 8:50 AM | Updates in Advanced Melanoma Management | Jeffrey S. Weber, MD, PhD |
| 9:05 AM | TBA | TBA |
| 9:20 AM | Management of Immuno-Oncology (IO) Toxicity | Shaheer A. Khan, DO |
| 9:35 AM | Panel Discussion and Question-and-Answer | All Faculty |
| 9:50 AM | Break (Exhibit Hall Open) | |
| Keynote Lectures | | Moderator: TBA |
| 10:20 AM | Giants of Cancer Care Introduction | TBA |
| 10:25 AM | Giants of Cancer Care Lecture | TBA |
| 10:45 AM | Question-and-Answer | |
| 10:55 AM | Greenspan Lecture Introduction | TBA |
| 11:00 AM | Greenspan Lecture | TBA |
| 11:30 AM | Question-and-Answer | |
| 11:40 AM | Celebrity Introduction | TBA |
| 11:45 AM | Celebrity Lecture | TBA |
| 12:05 PM | Question-and-Answer Session | |
| 12:15 PM | Lunch/Non-CE Symposia | |
| 1:30 PM | Welcome, Introductions, and Pre-session Survey | |
| 1:35 PM | Sarcoma topic | TBA |
| Breast Cancer | | Moderators: Nina D'Abreo, MD; and Tiffany A. Traina, MD |
| 1:50 PM | Metastatic Triple-Negative Breast Cancer (TNBC) | Nour Abuhadra, MD |
| 2:05 PM | Early-Stage Triple-Negative Breast Cancer (TNBC) | Tiffany A. Traina, MD |
| 2:20 PM | How to Sequence HER2-Directed Therapies in MBC | Shanu Modi, MD |
| 2:35 PM | Medical Crossfire®: Actionable Germline and Somatic Genetic Mutations in Breast Cancers | Moderator: Nina D'Abreo, MD Panelists: Aditya Bardia, MD, MPH; Sarat Chandarlapaty, MD, PhD; Mark E. Robson, MD; Joseph A. Sparano, MD |
| 2:55 PM | Panel Discussion and Question-and-Answer | All Faculty |
| 3:10 PM | Break (Exhibit Hall Open) | |
| 3:40 PM | Early-Stage ER+ Breast Cancer | Joseph A. Sparano, MD |
| 3:55 PM | Beyond Targeting ER in ER+ MBC | Sarat Chandarlapaty, MD, PhD |
| 4:10 PM | Current and Emerging Antibody-Drug Conjugates (ADCs) | Aditya Bardia, MD, MPH |
| 4:25 PM | What Your Breast Surgeon Needs You to Know | Freya Schnabel, MD |
| 4:40 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 4:55 PM | Closing Remarks/Adjourn | |
| 5:05 PM | Non-CE Symposia | |

BENEFITS OF ATTENDING

- Take part in our 40th anniversary celebration!
- Learn the best practices for incorporating the latest clinical data and evidence-based strategies into your practice from expert clinicians
- Gain insights from leading thought leaders on how best to address areas of clinical uncertainty
- Network with the top minds in oncology and hematology
- 100 experts, 25 tumor types, 3 days, 1 meeting.
- The 40th Annual CFS® has something for everyone!



Friday, November 11, 2022

| | | |
|------------------------------------|--|---|
| 7:00 AM | Welcome, Introductions, and Pre-session Survey | Benjamin P. Levy, MD |
| Lung Cancers | | Moderators: Alexander E. Drilon, MD; Benjamin P. Levy, MD |
| 7:15 AM | Role of Immuno-Oncology (IO) and Targeted Therapies in Early-Stage Lung Cancer | Jamie E. Chaft, MD |
| 7:30 AM | Competing Frontline Immunotherapy-Inclusive Strategies in Non-Small Cell Lung Cancer (NSCLC) | Hossein Borghaei, DO, MS |
| 7:45 AM | Antibody-Drug Conjugates (ADCs) for Non-Driver NSCLC | Melissa L. Johnson, MD |
| 8:00 AM | Optimizing Testing Strategies: How to Leverage Liquid Biopsy In the Diagnostic Algorithm | Charu Aggarwal, MD, MPH |
| 8:15 AM | Targeting Gene Fusions in Adenocarcinoma | Justin F. Gainor, MD |
| 8:30 AM | New Therapies for Emerging Targets | Gregory Riely, MD, PhD |
| 8:45 AM | Evolving Treatment Strategies for EGFR-Mutated Lung Cancer, Including Exon 20 | Helena A. Yu, MD |
| 9:00 AM | Small Cell Lung Cancer | Stephen V. Liu, MD |
| 9:15 AM | Medical Crossfire®: Adjuvant or Neoadjuvant IO? Single-Station IIIA, N2, PD-L1-Negative Disease | Moderator: Benjamin P. Levy, MD Panelists: Hossein Borghaei, DO, MS; Jamie E. Chaft, MD; Justin F. Gainor, MD; Mark A. Socinski, MD; |
| 9:35 AM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 9:50 AM | Break (Exhibit Hall Open) | |
| Head, Neck, Thyroid Cancers | | Moderator: Alan L. Ho, MD, PhD |
| 10:20 AM | IO Therapy for Squamous Cell Carcinoma of Head and Neck (HN) | Ranee Mehra, MD |
| 10:35 AM | Emerging Biomarkers and Treatment Paradigms for HPV-Positive HN | Glenn J. Hanna, MD |
| 10:50 AM | Therapeutics for Thyroid Cancer | Alan L. Ho, MD, PhD |
| 11:05 AM | Panel Discussion and Question-and-Answer Session | All Faculty |
| Pan Tumor Topic | | Moderator: TBA |
| 11:20 AM | Management of Brain and Leptomeningeal Metastases Across Tumor Types | TBA |
| 11:35 AM | Lunch/Non-CE Symposia | |
| 12:50 PM | Welcome, Introductions, and Pre-session Survey | |
| GI Cancers | | Moderator: Diane Reidy-Lagunes, MD |
| 12:55 PM | Novel Approaches to Treatment Spectrum of Biliary Cancers | Milind Javle, MD |
| 1:10 PM | Integrating and Sequencing Therapy for Hepatocellular Carcinoma (HCC) | James J. Harding, MD |
| 1:25 PM | ctDNA: an Emerging Tool in GI Cancers | Olatunji B. Alese MD |
| 1:40 PM | Approach to Neuroendocrine Malignancies in 2022 | Diane Reidy-Lagunes, MD |
| 1:55 PM | Total Neoadjuvant Therapies for Rectal Cancer: Key Considerations | TBA |
| 2:10 PM | Medical Crossfire®: Controversial Issues in Localized GE Cancer: Radiation vs Chemo | Moderator: Diane Reidy-Lagunes, MD Panelists: TBA |
| 2:30 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 2:45 PM | Break (Exhibit Hall Open) | |
| Genitourinary Cancers | | Moderators: Daniel P. Petrylak, MD and Scott T. Tagawa, MD, MS, FACP |
| 3:15 PM | Frontline Options for Advanced Clear-Cell Renal Cell Carcinoma (RCC) | Primo N. Lara, Jr., MD |
| 3:30 PM | What's New in Adjuvant Therapy for RCC | Ana M. Molina, MD |
| 3:45 PM | Perioperative Chemotherapy/Immunotherapy for Muscle-Invasive Urothelial Carcinoma | Jonathan E. Rosenberg, MD |
| 4:00 PM | Sequencing Therapy Throughout the Urothelial Carcinoma Treatment Continuum | Daniel P. Petrylak, MD |
| 4:15 PM | Emerging Therapeutic Radioligands for Advanced Prostate Cancer | Scott T. Tagawa, MD, MS, FACP |
| 4:30 PM | Optimizing Use of PARP Inhibitors for Prostate Cancer | Matthew Dallos, MD |
| 4:45 PM | Medical Crossfire®: What Is the Optimal Therapeutic Regimen for Hormone-Sensitive Prostate Cancer? | Moderator: Daniel P. Petrylak, MD Panelists: Matthew Dallos, MD; Susan F. Slovin, MD, PhD; Scott T. Tagawa, MD, MS, FACP |
| 5:05 PM | Panel Discussion and Question-and-Answer | All Faculty |
| 5:20 PM | Closing Remarks/Adjourn | |
| 5:30 PM | Non-CE Symposia | |

NURSING TRACK – WEDNESDAY

| | | |
|---------|---|-------------|
| 1:30 PM | Welcome, Introductions, and Pre-session Survey | |
| 1:40 PM | Clinical Update on CAR T-Cell Therapy | TBA |
| 2:00 PM | Adverse Event Management for Antibody-Drug Conjugates | TBA |
| 2:20 PM | Monitoring and Managing Toxicities Associated With Immune Checkpoint Inhibitors | TBA |
| 2:40 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 2:55 PM | Break | |
| 3:20 PM | Stress Management Strategies to Maintain Well-Being in the Workplace | TBA |
| 3:40 PM | Assessing Health Literacy to Improve Patient Education | TBA |
| 4:00 PM | Achieving Health Equity for Our Patients | TBA |
| 4:20 PM | TBA | TBA |
| 4:40 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 5:00 PM | Closing Remarks/Adjourn | |

HOW I DO IT TRACK – THURSDAY

| | | |
|---------|--|----------------------------|
| 1:30 PM | Welcome, Introductions, and Pre-session Survey | TBA |
| 1:40 PM | How to Administer Bispecific Drugs | TBA |
| 2:00 PM | How I Manage Older Patients With Cancer | TBA |
| 2:20 PM | How I Treat Neuroendocrine Carcinomas | Christine L. Hann, MD, PhD |
| 2:40 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 2:50 PM | Break | |
| 3:10 PM | TBA | TBA |
| 3:30 PM | TBA | TBA |
| 3:50 PM | TBA | TBA |
| 4:10 PM | Panel Discussion and Question-and-Answer Session | All Faculty |
| 4:20 PM | Adjourn | |
| 5:00 PM | Closing Remarks/Adjourn | |

REGISTRATION FEES

IN-PERSON

ADVANCED ON-SITE

| | | |
|-------------------------|-------|-------|
| Physicians | \$599 | \$699 |
| Fellows | \$249 | \$349 |
| Nurses, PAs, other HCPs | \$249 | \$349 |
| Industry | \$749 | \$849 |

VIRTUAL

ADVANCED

| | |
|-------|-------|
| \$399 | \$429 |
| \$149 | \$179 |
| \$149 | \$179 |
| \$675 | \$699 |

TWO WAYS TO REGISTER



gotoper.com/cfs22

or



609-378-3701

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credit™.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669.

PTce

Accreditation/Credit Designation for Pharmacists

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE).

Personal Protection Protocols

At Physicians Education Resource®, At Physicians Education Resource®, our top priority is the safety and security of attendees, faculty, staff, and operational personnel. As we develop the programming for this activity, PER® is working diligently to implement health and safety protocols based on the advice of health experts and the latest guidelines and local regulations to mitigate the risk of exposure to COVID-19 and to optimize health and safety conditions for attendees during the event.



STAY AROUND FOR SATURDAY

17th Annual New York **LUNG CANCERS** SYMPOSIUM[®]

IN-PERSON + VIRTUAL INTERACTIVE CONFERENCE
NOVEMBER 12, 2022 • 7:00 AM – 5:30 PM ET
InterContinental New York Barclay

BENEFITS OF ATTENDING

- Explore challenging cases from community physicians and see if your practice patterns match those of your colleagues
- Have all your burning clinical questions answered during one of several multidisciplinary tumor boards
- Get a “sneak peek” of upcoming advances in local and systemic therapies for thoracic malignancies and how they may best fit into treatment paradigms
- Attend a special session specifically designed for the educational needs of advanced practice providers

PROGRAM CO-CHAIRS



Balazs Halmos, MD, MS
Professor of Clinical Medicine
Director, Thoracic/Head and Neck
Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of
Medicine/Montefiore Medical Center
Bronx, NY



Mark G. Kris, MD
William and Joy Ruane Chair in Thoracic
Oncology
Memorial Sloan Kettering Cancer Center
New York, NY



To learn more, scan with your
smartphone or visit the link below